Inhibitory effect of argatroban on thrombin-induced MAP kinase activation.
A
A
Hijikata-Okunomiya
Y
Y
Nakaya
A
A
Takahashi
N
N
Inoue
T
T
Taniguchi
Y
Y
Ishikawa
D000818:Animals; D000991:Antithrombins / Q000494:pharmacology*; D001120:Arginine / Q000031:analogs & derivatives; D017871:Calcium-Calmodulin-Dependent Protein Kinases / Q000378:metabolism*; D002478:Cells, Cultured; D004336:Drug Antagonism; D004789:Enzyme Activation / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000201:enzymology*; D010875:Pipecolic Acids / Q000494:pharmacology*; D051381:Rats; D013449:Sulfonamides; D013917:Thrombin / Q000494:pharmacology*
D000991:Antithrombins; D010875:Pipecolic Acids; D013449:Sulfonamides; D001120:Arginine; D017871:Calcium-Calmodulin-Dependent Protein Kinases; D013917:Thrombin; C031942:argatroban